Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development

被引:30
作者
Andreas, C. J. [1 ]
Rosenberger, J. [1 ]
Butler, J. [2 ]
Augustijns, P. [3 ]
McAllister, M. [4 ]
Abrahamsson, B. [5 ]
Dressman, J. [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Pharmaceut Technol, Frankfurt, Germany
[2] GlaxoSmithKline R&D, Prod Dev & Supply, Ware, Herts, England
[3] Katholieke Univ Leuven, Drug Delivery & Disposit, Leuven, Belgium
[4] Pfizer PGRD, Drug Prod Design, Sandwich, Kent, England
[5] AstraZeneca R&D, Dept Global Med Dev, Molndal, Sweden
关键词
Dissolution; Decision tree; Formulation; Oral absorption; PBPK; Biopharmaceutics classification system (BCS); TRANSFER BIOGIT SYSTEM; SOLUBLE WEAK BASE; GASTROINTESTINAL TRANSFER; VIVO PERFORMANCE; SMALL-INTESTINE; DISSOLUTION MEDIA; DRUG ABSORPTION; TEST APPARATUS; TEST DEVICE; MODELS;
D O I
10.1016/j.ejpb.2018.07.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The EU research initiative OrBiTo (oral biopharmaceutics tools) involving partners from academia, pharmaceutical industry, small medium enterprises and a regulatory agency was launched with the goal of improving tools to predict the absorption of drugs in humans and thereby accelerating the formulation development process. The OrBiTo project was divided into four work packages (WP), with WP2 focusing on characterization of drug formulations. The present work introduces the OrBiTo WP2 Decision Tree, which is designed to assist the investigator in choosing the most appropriate in vitro methods for optimizing the oral formulation design and development process. The WP2 Decision Tree consists of four stages to guide the investigator. At the first stage, the investigator is asked to choose the formulation type of interest. At the second stage, the investigator is asked to identify which type of equipment (compendial/modified/noncompendial) is preferred/available. At the third stage, characteristics of the active pharmaceutical ingredient (API) are evaluated and in the fourth stage of the decision tree, suitable experimental protocols are recommended. A link to the living Decision Tree document is provided, and we now invite the pharmaceutical sciences community to apply it to current research and development projects and offer suggestions for improvement and expansion.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 39 条
  • [1] Mechanistic investigation of the negative food effect of modified release zolpidem
    Andreas, Cord J.
    Pepin, Xavier
    Markopoulos, Constantinos
    Vertzoni, Maria
    Reppas, Christos
    Dressman, Jennifer B.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 102 : 284 - 298
  • [2] Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine
    Andreas, Cord J.
    Tomaszewska, Irena
    Muenster, Uwe
    van der Mey, Dorina
    Mueck, Wolfgang
    Dressman, Jennifer B.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2016, 105 : 193 - 202
  • [3] In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release
    Andreas, Cord J.
    Chen, Ying-Chen
    Markopoulos, Constantinos
    Reppas, Christos
    Dressman, Jennifer
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 97 : 39 - 50
  • [4] Application and Validation of an Advanced Gastrointestinal In Vitro Model for the Evaluation of Drug Product Performance in Pharmaceutical Development
    Barker, Richard
    Abrahamsson, Bertil
    Kruusmagi, Martin
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (11) : 3704 - 3712
  • [5] Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System
    Berben, Philippe
    Brouwers, Joachim
    Augustijns, Patrick
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 107 (01) : 250 - 256
  • [6] Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs
    Bergstrom, Christel A. S.
    Holm, Rene
    Jorgensen, Soren Astrup
    Andersson, Sara B. E.
    Artursson, Per
    Beato, Stefania
    Borde, Anders
    Box, Karl
    Brewster, Marcus
    Dressman, Jennifer
    Feng, Kung-I.
    Halbert, Gavin
    Kostewicz, Edmund
    McAllister, Mark
    Muenster, Uwe
    Thinnes, Julian
    Taylor, Robert
    Mullertz, Anette
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 57 : 173 - 199
  • [7] Advances and challenges in PBPK modeling - Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base
    Berlin, Mark
    Ruff, Aaron
    Kesisoglou, Filippos
    Xu, Wei
    Wang, Michael Hong
    Dressman, Jennifer B.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 93 : 267 - 280
  • [8] Prediction of oral absorption of cinnarizine - A highly supersaturating poorly soluble weak base with borderline permeability
    Berlin, Mark
    Przyklenk, Karl-Heinz
    Richtberg, Annette
    Baumann, Wolfgang
    Dressman, Jennifer B.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (03) : 795 - 806
  • [9] IVIVC in Oral Absorption for Fenofibrate Immediate Release Tablets Using a Dissolution/Permeation System
    Buch, Philipp
    Languth, Peter
    Kataoka, Makoto
    Yamashita, Shinji
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (06) : 2001 - 2009
  • [10] Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model
    Carino, SR
    Sperry, DC
    Hawley, M
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) : 116 - 125